ethyl 4-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylate | 168272-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 4-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylate
• 英文别名: 4-bromomethyl-5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-1H-pyrazole-3-carboxylic acid ethyl ester；Ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-bromomethylpyrazole-3-carboxylate；ethyl 4-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)pyrazole-3-carboxylate
• CAS: 168272-91-1
• 化学式: C₁₉H₁₄BrCl₃N₂O₂
• 分子量: 488.595
• InChiKey: VSSBFDQWDSLXQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylate 在 aluminum (III) chloride 、 silver nitrate 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 20.0h， 生成 5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-hydroxymethyl-1H-pyrazole-3-carboxylic acid cyclohexylamide
  参考文献：
  名称：

  WO2006/133926

  摘要：

  公开号：
• 作为产物：
  描述：

  5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-羧酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 生成 ethyl 4-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  Pyrazole derivatives, method for preparing same, and pharmaceutical

  摘要：

  式(I)的化合物，其中R.sub.1是氟、羟基、(C.sub.1-5)烷氧基、(C.sub.1-5)烷基硫醚、羟基(C.sub.1-5)烷氧基、-NR.sub.10 R.sub.11基团、氰基、(C.sub.1-5)烷基磺酰基或(C.sub.1-5)烷基亚磺酰基；R.sub.2和R.sub.3分别是(C,.sub.4)烷基或与它们所连接的氮原子一起形成饱和或不饱和的5-至10-成员杂环基团，该基团可选择地被(C.sub.1-3)烷基或(C.sub.1-3)烷氧基取代一次或多次；R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8和R.sub.9中的每一个都是独立的氢、卤素或三氟甲基，当R.sub.1是氟时，R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8和/或R.sub.9也可以是氟甲基；但要注意的是，R.sub.4或R.sub.7的至少一个取代基不是氢；R.sub.10和R.sub.11中的每一个都是独立的氢或(C.sub.1-5)烷基，或者R.sub.10和R.sub.11与它们所连接的氮原子一起形成从吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基中选择的杂环基团，该杂环基团可选择地被(C.sub.1-4)烷基取代；公开了制备这些化合物的方法以及含有这些化合物的药物组合物。这些化合物对中枢大麻素受体具有非常高的亲和力。##STR1##

  公开号：

  US06028084A1

文献信息

• Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists
  申请人：LEE Jinhwa

  公开号：US20080081812A1

  公开（公告）日：2008-04-03

  A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB 1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

  一种异芳基-吡唑化合物，其公式为(I)或其药用可接受盐，可作为大麻素CB1受体的反向激动剂或拮抗剂，用于预防或治疗肥胖及其相关代谢紊乱。本发明还提供了制备本发明的异芳基-吡唑化合物或其药用可接受盐的方法，包含该化合物的药物组合物，以及用于预防或治疗肥胖及其相关代谢紊乱的方法。
• Pyrazole-3-carboxamide derivatives, process for their preparation and
  申请人：Sanofi

  公开号：US05462960A1

  公开（公告）日：1995-10-31

  The present invention relates to novel pyrazole-3-carboxamide derivatives of the formula ##STR1## in which the substituents are as defined in the specification. The present invention further relates to a process for the preparation of these novel derivatives and to the pharmaceutical compositions in which they are present.

  本发明涉及一种新型的吡唑-3-羧酰胺衍生物，其化学式为##STR1##其中取代基如规范中定义。本发明还涉及一种制备这些新型衍生物的方法，以及它们存在的药物组合物。
• [EN] FUSED PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRAZOLE CONDENSÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR CANNABINOÏDE
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2009095752A1

  公开（公告）日：2009-08-06

  The present invention relates to novel cannabinoid receptor modulators of formula (I), in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenrative disorders, eating disorders, weight loss or control, and obesity).

  本发明涉及一种新型的大麻素受体调节剂，其化学式为(I)，特别是大麻素1（CB1）或大麻素2（CB2）受体调节剂，以及用于治疗由大麻素受体调节的疾病、症状和/或疾患（如疼痛、神经退行性疾病、进食障碍、体重减轻或控制以及肥胖症）的用途。
• PYRAZOLE COMPOUNDS
  申请人：Shia Kak-Shan

  公开号：US20130085126A1

  公开（公告）日：2013-04-04

  Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , and X are defined herein. Also disclosed are pharmaceutical compositions and methods related to use of these compounds.

  式（I）的化合物：其中R1、R2、R3、R4、R5和X在此处定义。还披露了与这些化合物的使用相关的药物组合物和方法。
• Pyrazole derivatives, method for preparing same, and pharmaceutical
  申请人：Sanofi-Synthelabo

  公开号：US06028084A1

  公开（公告）日：2000-02-22

  Compounds of formula (I), wherein R.sub.1 is fluorine, hydroxy, (C.sub.1-5) alkoxy, (C.sub.1-5) alkylthio, hydroxy(C.sub.1-5)alkoxy, a -NR.sub.10 R.sub.11, group, cyano, (C.sub.1-5) alkyl-sulphonyl or (C.sub.1-5) alkylsulphinyl; R.sub.2 and R.sub.3 are each (C,.sub.4) alkyl or, taken together with the nitrogen atom to which they are attached, form a saturated or unsaturated 5- to 10-membered heterocyclic radical optionally substituted one or more times by (C.sub.1-3) alkyl or (C.sub.1-3) alkoxy; each of R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is independently hydrogen, halogen or trifluoromethyl, and when R.sub.1 is fluorine, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and/or R.sub.9 may also be fluoromethyl; with the proviso that at least one of substituents R.sub.4 or R.sub.7. is other than hydrogen; each of R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-5) alkyl, or R.sub.10 and R.sub.11, taken together with the nitrogen atom to which they are attached, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl optionally substituted by (C.sub.1-4) alkyl; a method for preparing same, and pharmaceutical compositions containing said compounds, are disclosed. Said compounds have very high affinity for central cannabinoid receptors. ##STR1##

  式(I)的化合物，其中R.sub.1是氟、羟基、(C.sub.1-5)烷氧基、(C.sub.1-5)烷基硫醚、羟基(C.sub.1-5)烷氧基、-NR.sub.10 R.sub.11基团、氰基、(C.sub.1-5)烷基磺酰基或(C.sub.1-5)烷基亚磺酰基；R.sub.2和R.sub.3分别是(C,.sub.4)烷基或与它们所连接的氮原子一起形成饱和或不饱和的5-至10-成员杂环基团，该基团可选择地被(C.sub.1-3)烷基或(C.sub.1-3)烷氧基取代一次或多次；R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8和R.sub.9中的每一个都是独立的氢、卤素或三氟甲基，当R.sub.1是氟时，R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8和/或R.sub.9也可以是氟甲基；但要注意的是，R.sub.4或R.sub.7的至少一个取代基不是氢；R.sub.10和R.sub.11中的每一个都是独立的氢或(C.sub.1-5)烷基，或者R.sub.10和R.sub.11与它们所连接的氮原子一起形成从吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基中选择的杂环基团，该杂环基团可选择地被(C.sub.1-4)烷基取代；公开了制备这些化合物的方法以及含有这些化合物的药物组合物。这些化合物对中枢大麻素受体具有非常高的亲和力。##STR1##